JGP Wealth Management LLC Has $242,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

JGP Wealth Management LLC lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 29.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,003 shares of the medical instruments supplier’s stock after selling 416 shares during the period. JGP Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $242,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in BDX. Nordea Investment Management AB lifted its position in Becton, Dickinson and Company by 277.3% during the 1st quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock worth $478,295,000 after buying an additional 1,423,353 shares in the last quarter. PineStone Asset Management Inc. lifted its position in Becton, Dickinson and Company by 141.6% during the 2nd quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after buying an additional 788,735 shares in the last quarter. M&G Plc acquired a new position in Becton, Dickinson and Company during the 1st quarter worth about $173,692,000. First Eagle Investment Management LLC lifted its position in Becton, Dickinson and Company by 32.5% during the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after buying an additional 688,296 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after buying an additional 346,720 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $236.50 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The stock has a market cap of $68.35 billion, a PE ratio of 52.09, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The stock has a 50-day moving average of $236.37 and a 200-day moving average of $235.43. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.55.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.96 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were paid a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.61%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Evercore ISI upped their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.